120 Chemokine receptor engineering enhances trafficking and homing of primary and iPSC-derived CAR-T cells to solid tumors

• Tom Lee,
• Martin Hosking,
• Mochtar Pribadi,
• Yijia Pan,
• Bishwas Shrestha,
• Soheila Shirinbak,
• Angela Gentile,
• Jason ORourke,
• Bob Valamehr,
• Joy Grant,
• Amit Mehta,
• Bjoern Gaertner,
• Alec Witty

Affiliations

Tom Lee

1Fate Therapeutics, San Diego, CA, USA

Martin Hosking

1 Children`s Heart Centre, BC Children`s Hospital, Vancouver, British Columbia, Canada

Mochtar Pribadi

1Fate Therapeutics, San Diego, CA, USA

Yijia Pan

1Fate Therapeutics, San Diego, CA, USA

Bishwas Shrestha

Fate Therapeutics, Inc., San Diego, CA, USA

Soheila Shirinbak

Fate Therapeutics, Inc., San Diego, CA, USA

Angela Gentile

Fate Therapeutics, Inc., San Diego, CA, USA

Jason ORourke

Fate Therapeutics, Inc., San Diego, CA, USA

Bob Valamehr

2Fate Therapeutics, Inc., San Diego, CA, USA

Joy Grant

Fate Therapeutics, Inc., San Diego, CA, USA

Amit Mehta

Fate Therapeutics, Inc., San Diego, CA, USA

Bjoern Gaertner

Fate Therapeutics, Inc., San Diego, CA, USA

Alec Witty

Fate Therapeutics, Inc., San Diego, CA, USA